Prospective Trial of Synchronous Bevacizumab, Erlotinib, and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer
Clinical Cancer Research, 02/23/2012Yoo DS et al.
Dual VEGF/epidermal growth factor receptor (EGFR)R inhibition can be integrated with chemoradiation (CRT) in locally advanced head and neck cancer (HNC), with efficacy that compares favorably with historical controls albeit with an increased risk of osteoradionecrosis. Pretreatment and early DCE–MRI may prospectively identify patients at high risk of failure.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.